NEUROCRINE BIOSCIENCES INC
For the period ended Dec 31, 2023. Filed Feb 9, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 9, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Our corporate headquarters are located in San Diego, California. We believe that our property and equipment are generally well maintained, in good operating condition and suitable for the conduct of our business.
Details of our leased facilities, which include our corporate headquarters and consist of office space and research and development laboratories, follow.
| Address | Type | Square Feet |
|---|---|---|
| 12780 El Camino Real, San Diego, California | Office Space, Research and Development Laboratories | 141,000 |
| 6027 Edgewood Bend Court, San Diego, California | Office Space | 124,000 |
| 6029 Edgewood Bend Court, San Diego, California | Office Space | 110,000 |
| 12790 El Camino Real, San Diego, California | Office Space | 88,000 |
| 10420 Wateridge Circle, San Diego, California | Research and Development Laboratories | 46,000 |
| 12777 High Bluff Drive, San Diego, California | Office Space | 45,000 |
| 12770 El Camino Real, San Diego, California | Office Space | 26,000 |
On February 8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, including a six-year option for the construction of a fifth building. This campus facility, comprised of office space and research and development laboratories, will serve as our new corporate headquarters.
The construction of the campus facility is phased. The first phase of construction relating to office space was completed in December 2023. As we begin to occupy our new campus facility, we will sublease certain of our existing leased premises when we determine there is excess leased capacity.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.